Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RAD52 resolves transcription-replication conflicts to mitigate R-loop induced genome instability.
Jalan M, Sharma A, Pei X, Weinhold N, Buechelmaier ES, Zhu Y, Ahmed-Seghir S, Ratnakumar A, Di Bona M, McDermott N, Gomez-Aguilar J, Anderson KS, Ng CKY, Selenica P, Bakhoum SF, Reis-Filho JS, Riaz N, Powell SN. Jalan M, et al. Among authors: pei x. Nat Commun. 2024 Sep 5;15(1):7776. doi: 10.1038/s41467-024-51784-x. Nat Commun. 2024. PMID: 39237529 Free PMC article.
Large-scale copy number alterations are enriched for synthetic viability in BRCA1/BRCA2 tumors.
Zhu Y, Pei X, Novaj A, Setton J, Bronder D, Derakhshan F, Selenica P, McDermott N, Orman M, Plum S, Subramanyan S, Braverman SH, McMillan B, Sinha S, Ma J, Gazzo A, Khan A, Bakhoum S, Powell SN, Reis-Filho JS, Riaz N. Zhu Y, et al. Among authors: pei x. Genome Med. 2024 Aug 28;16(1):108. doi: 10.1186/s13073-024-01371-y. Genome Med. 2024. PMID: 39198848 Free PMC article.
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.
Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, Kuo F, Chung J, Srivastava RM, Purohit TA, Hoen DR, Mandal R, Setton J, Wu W, Shah R, Qeriqi B, Chang Q, Kendall S, Braunstein L, Weigelt B, Blecua Carrillo Albornoz P, Morris LGT, Mandelker DL, Reis-Filho JS, de Stanchina E, Powell SN, Chan TA, Riaz N. Samstein RM, et al. Among authors: pei x. Nat Cancer. 2021 Dec;1(12):1188-1203. doi: 10.1038/s43018-020-00139-8. Epub 2020 Nov 16. Nat Cancer. 2021. PMID: 33834176 Free PMC article.
Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.
Ma J, Shah R, Bell AC, McDermott N, Pei X, Selenica P, Haseltine J, Delsite R, Khan AJ, Lok BH, Ellis MJ, Aft RF, Setton J, Reis-Filho JS, Riaz N, Powell SN. Ma J, et al. Among authors: pei x. Int J Radiat Oncol Biol Phys. 2024 Jul 10:S0360-3016(24)02946-8. doi: 10.1016/j.ijrobp.2024.06.037. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38997095
The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers.
Mandelker D, Kumar R, Pei X, Selenica P, Setton J, Arunachalam S, Ceyhan-Birsoy O, Brown DN, Norton L, Robson ME, Wen HY, Powell S, Riaz N, Weigelt B, Reis-Filho JS. Mandelker D, et al. Among authors: pei x. JNCI Cancer Spectr. 2019 Apr 27;3(2):pkz027. doi: 10.1093/jncics/pkz027. eCollection 2019 Jun. JNCI Cancer Spectr. 2019. PMID: 31360903 Free PMC article.
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.
Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, Capanu M, Balachandran V, McIntyre CA, El Dika I, Khalil DN, Harding JJ, Ghalehsari N, McKinnell Z, Chalasani SB, Makarov V, Selenica P, Pei X, Lecomte N, Kelsen DP, Abou-Alfa GK, Robson ME, Zhang L, Berger MF, Schultz N, Chan TA, Powell SN, Reis-Filho JS, Iacobuzio-Donahue CA, Riaz N, O'Reilly EM. Park W, et al. Among authors: pei x. Clin Cancer Res. 2020 Jul 1;26(13):3239-3247. doi: 10.1158/1078-0432.CCR-20-0418. Epub 2020 May 22. Clin Cancer Res. 2020. PMID: 32444418 Free PMC article.
Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial.
Riaz N, Sherman E, Pei X, Schöder H, Grkovski M, Paudyal R, Katabi N, Selenica P, Yamaguchi TN, Ma D, Lee SK, Shah R, Kumar R, Kuo F, Ratnakumar A, Aleynick N, Brown D, Zhang Z, Hatzoglou V, Liu LY, Salcedo A, Tsai CJ, McBride S, Morris LGT, Boyle J, Singh B, Higginson DS, Damerla RR, Paula ADC, Price K, Moore EJ, Garcia JJ, Foote R, Ho A, Wong RJ, Chan TA, Powell SN, Boutros PC, Humm JL, Shukla-Dave A, Pfister D, Reis-Filho JS, Lee N. Riaz N, et al. Among authors: pei x. J Natl Cancer Inst. 2021 Jun 1;113(6):742-751. doi: 10.1093/jnci/djaa184. J Natl Cancer Inst. 2021. PMID: 33429428 Free PMC article. Clinical Trial.
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
Selenica P, Marra A, Choudhury NJ, Gazzo A, Falcon CJ, Patel J, Pei X, Zhu Y, Ng CKY, Curry M, Heller G, Zhang YK, Berger MF, Ladanyi M, Rudin CM, Chandarlapaty S, Lovly CM, Reis-Filho JS, Yu HA. Selenica P, et al. Among authors: pei x. Ann Oncol. 2022 Dec;33(12):1284-1295. doi: 10.1016/j.annonc.2022.09.151. Epub 2022 Sep 9. Ann Oncol. 2022. PMID: 36089134 Free PMC article.
2,444 results